Menu Search
Equities

AnGes Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AJW:DUS

AnGes Inc

Actions
  • Price (EUR)0.256
  • Today's Change-0.006 / -2.29%
  • Shares traded--
  • 1 Year change-0.78%
  • Beta1.1496
Data delayed at least 15 minutes, as of Feb 06 2026 18:31 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

  • Revenue in JPY (TTM)818.14m
  • Net income in JPY-25.66bn
  • Incorporated1999
  • Employees55.00
  • Location
    AnGes IncSaito Bio-Incubator, 7-7-15, Saito-AsagiIBARAKI-SHI 567-0085JapanJPN
  • Phone+81 357302641
  • Websitehttps://www.anges.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.